<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="181">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01363557</url>
  </required_header>
  <id_info>
    <org_study_id>P100601</org_study_id>
    <secondary_id>2010-A01332-37</secondary_id>
    <nct_id>NCT01363557</nct_id>
  </id_info>
  <brief_title>Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain Metastasis</brief_title>
  <acronym>ARPEGE</acronym>
  <official_title>Randomized to Assess the Efficacy of Whole Brain Radiation Therapy (WBRT) With Concomitant Gefitinib Followed by Maintenance Gefitinib, and Gefitinib Alone, in Lung Cancer Patients With Brain Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <authority>France: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicentre randomised (1:1) trial assessing the efficacy of whole brain radiotherapy in
      addition to Gefitinib for the management of brain metastasis in lung cancer patients with a
      mutated EGFR.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lung cancer patients with newly diagnosed CNS metastasis with-	at least one brain lesion
      measuring &gt; 1 cm in longest dimension -	not eligible for surgery or stereotactic
      radio-surgeryOpen-label, multicentre, national, randomised (1:1) phase II trialArm A: WBRT
      and Concurrent Gefitinib followed by Gefitinib Maintenance Arm B: Gefitinib
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To assess the objective response rate of brain metastases in each arm</measure>
    <time_frame>at 6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with neurological Adverse Events</measure>
    <time_frame>at 6 weeks, 3 months, 4.5 months and 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>at 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>at 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>EGFR-mutated Lung Adenocarcinoma</condition>
  <condition>Brain Metastasis</condition>
  <arm_group>
    <arm_group_label>Arm A : Gefitinib + WBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A : WBRT and Concurrent Gefitinib followed by Gefitinib Maintenance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B : Gefitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B : Gefitinib alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>whole brain radiotherapy</intervention_name>
    <description>External beam RT using a total dose of 30 Gy with ten daily fractions of 3.0 Gy given 5 days per week over 2 weeks + Gefitinib 250 mg/day</description>
    <arm_group_label>Arm A : Gefitinib + WBRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib (IRESSA)</intervention_name>
    <description>250 mg/day</description>
    <arm_group_label>Arm B : Gefitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have signed a written informed consent form prior to any study specific
             screening procedures

          -  18 years or older

          -  KPS ≥ 50%

          -  Histologically confirmed adenocarcinoma of the lung

          -  Activating mutation of EGFR

          -  Newly diagnosed CNS metastasis or in progression with at least one measurable lesion
             in the brain (defined as any lesion &gt; 1 cm on T1-weighted contrast enhanced MRI)

          -  Patients could enter the study regardless of previous treatment (included
             chemotherapy) for metastatic extracranial disease, except TKI.

          -  No steroids or stable or decreasing dose of steroids for at least 5 days before the
             MRI evaluation.

          -  Adequate hematologic, liver and renal functions: neutrophil count ≥   1.5 x 109/L;
             platelets ≥   100 x 109/L; Hb ≥ 9 g/Dl; Total bilirubin &lt; 1.5 x ULN; AST or ALT &lt; 2.5
             x ULN (&lt; 5 x ULN in patients with liver metastases); Serum creatinine ≤ 1.5 x ULN or
             Creatinine clearance ≥ 50 mL/min

        Exclusion Criteria:

          -  Prior treatment of brain metastases with WBRT or TKI

          -  Patient eligible for radiosurgery or surgical resection

          -  Contre indication at the radiotherapy

          -  Leptomeningeal disease

          -  Previous history of cancer (other than curatively treated basal and squamous cell
             carcinoma of the skin and/or in-situ carcinoma of the cervix) within the  the 5 years
             before study entry

          -  Prior treatment with Gefitinib or other TKI

          -  Pregnant or breast feeding women

          -  Women with an intact uterus (unless amenorrhoeic for the last 24 months) not using
             effective means of contraception
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoine CARPENTIER, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antoine CARPENTIER, MD,PhD</last_name>
    <phone>33 1 48 95 54 91</phone>
    <email>antoine.carpentier@avc.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service de Neurologie - Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>April 30, 2013</lastchanged_date>
  <firstreceived_date>May 25, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Randomized</keyword>
  <keyword>Brain Radiation Therapy</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Brain Metastasis</keyword>
  <keyword>Gefitinib</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Adenocarcinoma, Mucinous</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
